Filing Details

Accession Number:
0001179110-20-012070
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-17 18:58:55
Reporting Period:
2020-12-15
Accepted Time:
2020-12-17 18:58:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650664 Editas Medicine Inc. EDIT Biological Products, (No Disgnostic Substances) (2836) 464097528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1682323 Charles Albright C/O Editas Medicine, Inc.
11 Hurley St.
Cambridge MA 02141
Evp/Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-15 10,000 $16.51 34,907 No 4 M Direct
Common Stock Disposition 2020-12-15 5,776 $62.74 29,131 No 4 S Direct
Common Stock Disposition 2020-12-15 4,024 $63.84 25,107 No 4 S Direct
Common Stock Disposition 2020-12-15 200 $64.39 24,907 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-12-15 10,000 $0.00 10,000 $16.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
145,000 2026-09-08 No 4 M Direct
Footnotes
  1. The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
  2. This transaction was executed in multiple trades at prices ranging from $62.18 to $63.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $63.24 to $64.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020.